Predicting relapse in patients with inflammatory bowel disease: What is the role of biomarkers?

Gut

Volumn 54, Issue 3, 2005, Pages 321-322

  Pardi, D S ^a,b   Sandborn, W J ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALPROTECTIN; FIBRINOGEN; INDIUM 111; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRICIN; OROSOMUCOID; SERUM AMYLOID A; STEROID; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE MARKER; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FECES ANALYSIS; FECES LEVEL; GASTROINTESTINAL ENDOSCOPY; HUMAN; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; LEUKOCYTE; NOTE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; REFERENCE VALUE; RELAPSE; REMISSION; ULCERATIVE COLITIS; VALIDATION PROCESS;

BIOLOGICAL MARKERS; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; PROGNOSIS; RECURRENCE; SENSITIVITY AND SPECIFICITY;

EID: 14544277044     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.048850     Document Type: Note

References (18)

1. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative collitis than in Crohn's disease. Gut 2005;54:364-8.
2. Roseth AG, Schmidt TN, Fagerhol MK. Correlation between faecel excretion of indium 111-labeled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4.
3. Tibble JA, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease Gut 2000;47:506-13.
4. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
5. Roseth AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis 2003;35:607-9.
6. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
7. Mary JY, Modigliani R. Development and validation of an endoscopic index of severity for Crohn's disease: a prospective multicenre study. Gut 1989;30:983-9.
8. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn's disease: Monitoring disease activity. Aliment Pharmacol Ther 2003;17(suppl 2):11-17.
9. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
10. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biologic activity markers of inflammatory bowel disease. Am J Gastroenterol 2000;95:359-67.
11. Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index For predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986;91:1490-4.
12. Boirivant M, Leoni M, Taricotti D, et al. The clinical significance of serum C-reactive protein levels in Crohn's disease. J Clin Gastroenterol 1988;10:401-5.
13. Arnott IDR, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002;16:857-67.
14. van der Sluys Veer A, Biemond I, Verspaget HW, et al. Faecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol 1999;(suppl 230): 106-10.
15. Walker TR, Land ML, Cook TM, et al. Serial fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive inflammatory bowel disease. Gastroenterology 2004;126:A215.
16. Tibble JA, Bjarnason I. Noninvasive investigation of inflammatory bowel disease. World J Gastroenterol 2001;7:460-5.
17. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology 1995;108:1566-81.
18. Schreiber S, Nikolaus S, Hampe J, et al. Tumor necrosis factor alpha and interleukin 1 beta in relapse of Crohn's disease. Lancet 1999;353:459-61.